Literature DB >> 14509050

[Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].

Michael Philipp1, Otto M Lesch, Max Schmauss, Matthias Dose, Thomas Glaser.   

Abstract

The efficacy of flupentixol and risperidone were compared in a randomized double-blind study in 153 chronic schizophrenic patients. Flupentixol showed to be not inferior to risperidone concerning schizophrenic negative symptoms at week 8, 16 and 24. Positive symptoms and general psychopathology improved comparably, too. There was a trend in favor of flupentixol concerning the improvement of depressive symptoms and a trend in favor of risperidone concerning the improvement of preexisting parkinsonian symptoms. The study data justify to regard flupentixol as a "partial atypical" antipsychotic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14509050

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  2 in total

1.  Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Authors:  M Reimold; C Solbach; S Noda; J-E Schaefer; M Bartels; M Beneke; H-J Machulla; R Bares; T Glaser; H Wormstall
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

Review 2.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.